Divergent clonal evolution of castration resistant neuroendocrine prostate cancer

@inproceedings{Beltran2016DivergentCE,
  title={Divergent clonal evolution of castration resistant neuroendocrine prostate cancer},
  author={Himisha Beltran and Davide Prandi and Juan Miguel Mosquera and Matteo Benelli and Loredana Puca and Joanna Cyrta and Clarisse Marotz and Eugenia G. Giannopoulou and Balabhadrapatruni V S K Chakravarthi and Sooryanarayana Varambally and Scott Arthur Tomlins and David M. Nanus and Scott T. Tagawa and Eliezer M Van Allen and Olivier Elemento and Andrea Sboner and Levi A. Garraway and Mark A. Rubin and Francesca Demichelis},
  booktitle={Nature Medicine},
  year={2016}
}
An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to absent AR expression and often have neuroendocrine features. The etiology and molecular basis for this 'alternative' treatment-resistant cell state remain incompletely… CONTINUE READING